ArticleClinical lymphoma, myeloma & leukemia2014

A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.

James Foran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.